Sentences with phrase «of kinase inhibitors»

Figure 3: Effects of kinase inhibitors on actinomycin D (ActD)- induced p53 expression.

Figure 5: Effects of kinase inhibitors on p53 expression as revealed by immunofluorescence imaging.

Identification of kinase inhibitors that target transcription initiation by RNA polymerase II.

«They also suggest that interactions between oncologic kinases and SYK or other wild type enzymes may contribute to resistance of kinase inhibitors more broadly.»

However, advances in therapy have been made, notably the emergence of kinase inhibitors for patients whose disease relapsed, according to the study background.

And none of these kinase inhibitors have yet been rigorously tested in a head - to - head comparison with the protein therapies already on the market.

And within one of these kinase inhibitor libraries, the Colorado group found the PBK inhibitor HITOPK32.

This work, and that of colleagues Brian Druker and Novartis, led to the development of the kinase inhibitor imatinib (Gleevec) as primary therapy for chronic myelogenous leukemia (CML), and the discovery that imatinib resistance is caused by BCR - ABL kinase domain mutations.

Not exact matches

The authors also found that a novel small molecule inhibitor of the salvage pathway enzyme deoxycytidine kinase blocked leukemia growth in mice in combination with thymidine (to inhibit the de novo pathway).

Therefore, a novel therapeutic approach in inflammatory breast cancer could involve a combination of conventional chemotherapy with small - molecule inhibitors of the Cdk2 cell cycle kinase.

These results not only show promise on a new targeted therapy to treat this malignancy, as PI3K inhibitors are already used in the clinical practice, but also unravel a new function of the PI3K kinase in cancer biology through its role in promoting metastasis.

The estimation of EGFR mutation status is essential for the identification of non-small cell lung carcinoma (NSCLC) patients who may benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs), and hence for improving therapeutic efficacy.

Imatinib is an inhibitor that blocks the ATP - binding site of the tyrosine kinase Abl in affected blood cells, thereby suppressing their overactivity.

These studies will investigate whether Src kinase inhibitors are best used in the adjuvant setting post-surgery or after chemotherapy to prevent the formation of local and distant disease recurrence.

One of the more intriguing findings in the study was that increasing histone crotonylation works synergistically with other known anti-HIV latency molecules, such as the protein kinase C agonist PEP005 and the HDAC inhibitor vorinostat.

They looked at other genes that interacted with TAK1 kinase including activators and inhibitors of the TAK1 pathway and found that most of them also affected regeneration, but only when worms were infected.

But major pharmaceutical laboratories are investigating highly selective inhibitors of this molecular linchpin, many of them targeted at the enzymes (such as I - kB kinase) that regulate NF - kB activity.

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.

Vemurafenib joins other multi-targeted kinase inhibitors (MKIs)(sorafenib, lenvatinib) shown to be effective in this patient population; in spite of responses to these drugs, the responses are temporary and additional treatment options are needed.

(Moussa is listed as an inventor on a patent application that Georgetown University filed related to nilotinib and the use of other tyrosine kinase inhibitors for the treatment of neurodegenerative diseases.)

This finding is the latest from Georgetown University Medical Center's Translational Neurotherapeutics Program (TNP) examining tyrosine kinase inhibitors in the treatment of neurodegenerative diseases.

«Patients with non-small cell lung cancer (NSCLC) should receive front line therapy with the anaplastic lymphoma kinase (ALK) inhibitor crizotinib,» said lead author Professor Giorgio Scagliotti, head of the Department of Oncology, University of Turin, Italy.

Dinaciclib is a member of a class of drugs known as cyclin - dependent kinase (CDK) inhibitors.

In experiments using enzyme inhibitors, the possibility that cinnamtannin B - 1 enhanced mobilization through the use of activation of enzymes such as PI3 kinase near the cell membrane was shown.

Pao was involved in studies of EGFR tyrosine - kinase inhibitors while at MSKCC, where he trained in medical oncology.

PKIS2 is a collection of more than 500 kinase inhibitors donated by GSK, Pfizer and Takeda Pharmaceuticals that SGC - UNC makes available to the scientific community.

The Structural Genomics Consortium at the University of North Carolina at Chapel Hill (SGC - UNC), in partnership with the DiscoverX Corporation, has reached the milestone halfway point in its development of the Kinase Chemogenomic Set, a potent group of inhibitors which allow deeper exploration of the human kinome, a family of enzymes critical to understanding human disease and developing new therapies.

While more than 30 kinase inhibitors have been approved for the treatment of disease, the kinome has been largely unexplored until SGC - UNC, DiscoverX and other SGC partner companies embarked on this project.

Approximately 10 - 15 % of Caucasian and 30 - 35 % of Asian patients with NSCLC have a mutation in the epidermal growth factor receptor (EGFR), which can be successfully targeted with EGFR inhibitors called tyrosine kinase inhibitors (TKI), such as erlotinib, gefitinib and afatinib.

THE STUDIES A trilogy of papers published in the September 28 issue of Nature examine the role of a protein — cyclin - dependent kinase inhibitor p16INK4a — in aging, healing, and cancer.

«Through our collaboration with DiscoverX, we screened a large set of compounds that we call Published Kinase Inhibitor Set 2, and these results allowed us to reach the halfway point in constructing the KCGS» said David Drewry, a research associate professor at the UNC Eshelman School of Pharmacy and SGC - UNC principal investigator who is leading the project to develop the Kinase Chemogenomic Set.

And it turns out that bosutinib may inhibit the activity of exactly the kinases that EGFR - dependent lung cancers need to mutate around the challenge of EGFR inhibitors.

It's been an important question — many lung cancers depend on over-activation of the gene EGFR, but then when EGFR inhibitors like gefitinib or erlotinib are used, the cancers tend to activate other «kinases» that allow the cancer to by - pass around this dependence.

If this is true, then immunocheckpoint blockade combination with EGFR tyrosine kinase inhibitors is a major path towards improving outcome of patients who have EGFR - mutant non-small-cell lung cancer.»

In a proof - of - concept study, Fourches and Ash looked at the ERK2 kinase — an enzyme associated with several types of cancer — and a group of 87 known ERK2 inhibitors, ranging from very active to inactive.

The presence of a germline EGFR T790M mutation also predicts for resistance to standard tyrosine kinase inhibitors (TKIs), which adds complexity to treatment.

An international research group has now shown that there is another, equally effective oral treatment option: the combination of methotrexate and the chemically synthesised Janus Kinase Inhibitor tofacitinib.

This visual abstract depicts how Wei et al. utilize single - cell phosphoproteomic analysis of patient derived glioblastoma models to identify shifts in signaling coordination following short - term treatment with kinase inhibitors, which facilitates the design of combination therapy approaches with reduced resistance and improved efficacy.

As the name suggests, kinase inhibitors interrupt the function of kinases — a particular type of enzyme — and effectively shut down the activity of proteins that contribute to cancer.

The researchers, including scientists from pharmaceutical company AstraZeneca, report in an advanced online publication in Nature Medicine on May 4, that their findings indicate «an underappreciated genomic heterogeneity» in mechanisms of resistance to tyrosine kinase inhibitor (TKI) drugs that target the Epidermal Growth Factor Receptor (EGFR) mutation that drive some cases of non-small cell lung cancer (NSCLC).

Focusing on a particular group of enzyme - blocking compounds called protein kinase inhibitors, they identified 31 compounds that inhibit malaria growth without harming the host.

Many kinase inhibitors possess axes of chirality that are freely spinning.

A class of therapeutic drugs known as protein kinase inhibitors has in the past decade become a powerful weapon in the fight against various life - threatening diseases, including certain types of leukemia, lung cancer, kidney cancer and squamous cell cancer of the head and neck.

These therapies, the first an antibody and the second of a class called tyrosine kinase inhibitors (TKIs), reduce the ability of a target gene to manufacture the protein it encodes.

Rho - kinase inhibitor treatment increased the cellular proliferation up to twofold during the first 12 h, and a wound model based migration assay showed 50 % faster filling of the mechanically generated wound area.

A number of pharmaceutical companies offer libraries of inhibitors against hundreds or thousands of kinases.

Kinases are also druggable targets, as seen by the success of kinase - inhibitors in earning FDA approval (including, for example, crizotinib against ALK - fusion and erlotinib against EGFR).

A class of oral specialty drugs, tyrosine kinase inhibitors (TKIs), has revolutionized the treatment of CML, largely transforming it into a chronic condition and enabling many patients to have a near - normal lifespan, particularly when compared to a median survival of less than three years with prior therapies.

This thesis primarily investigates the effects of mechanical cyclic stretching, a 5 % low oxygen atmosphere and the Rho - kinase inhibitor, Y - 27632, on protein responses in chondrocytic human chondrosarcoma (HCS - 2 / 8) cells.

In 2005, Cagan's team created a general fly model of a human thyroid tumor caused by mutations in the Ret receptor tyrosine kinase gene, then screened a panel of drugs including a kinase inhibitor called vandetanib that suppressed the tumor (Cancer Res, 65:3538 - 41, 2005).